Abstract
MA23.01 Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have